sunitinib (Sutent)
Jump to navigation
Jump to search
Indications
- treatment of renal cell carcinoma
- adults at risk for recurrent renal cell carcinoma following nephrectomy[8]
- treatment of imatinib-resistant gastrointestinal stromal tumor
- treatment of hepatocellular carcinoma[6]
- islet cell tumor[7]
Dosage
Capsules: 12.5 mg, 25 mg or 50 mg
Adverse effects
- cardiovascular events
- skin & tissue problems (rash), hands, feet[6]
- gastrointestinal events
- hemorrhage
- hypertension
- hematological problems
- venous thromboembolism
- hypothyroidism
Drug interactions
- several reports of microangiopathic hemolytic anemia in patients with solid tumors receiving Avastin in combination with sunitinib malate; this combination is not recommended[2]
Laboratory
Mechanism of action
- tyrosine kinase inhibitor
- inhibits CSF1R, VEGF receptor, PDGF receptor, raf[6]
More general terms
References
- ↑ Prescriber's Letter 14(2): 2007 New drugs approved by the FDA in 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=2302213&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Jump up to: 2.0 2.1 FDA Medwatch http://www.fda.gov/medwatch/safety/2008/safety08.htm#Avastin
- ↑ Sutent http://www.sutent.com/
- ↑ National Cancer Institute: Sunitinib Malate http://www.cancer.gov/cancertopics/druginfo/sunitinibmalate
Wikipedia: Sunitinib http://en.wikipedia.org/wiki/Sunitinib - ↑ RxList Sutent http://www.rxlist.com/sutent-drug.htm
- ↑ Jump up to: 6.0 6.1 6.2 6.3 Medical Knowledge Self Assessment Program (MKSAP) 16, 17 American College of Physicians, Philadelphia 2012, 2015
- ↑ Jump up to: 7.0 7.1 Deprecated Reference
- ↑ Jump up to: 8.0 8.1 FDA News Release. November 16, 2017 FDA expands approval of Sutent to reduce the risk of kidney cancer returning. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm585657.htm